|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 12,138,245
Summary
U.S. Patent 12,138,245, granted to Vaxcyte Inc. in October 2021, pertains to a novel vaccine technology platform focused on generating broad immune responses against bacterial pathogens. Its core claimed innovation involves specific conjugate compositions and methods for inducing immune protection. This document provides a comprehensive analysis of its scope, claims, and the landscape, including key competitors, technological trends, and patent family networks.
What is the Scope of U.S. Patent 12,138,245?
Scope overview:
The patent primarily defines a conjugate vaccine platform designed to enhance immunogenicity by utilizing novel carrier proteins or conjugation methods targeting bacterial polysaccharides. It encompasses compositions, processes for manufacturing, and methods for eliciting immune responses against pathogenic bacteria, notably Streptococcus pneumoniae, Haemophilus influenzae, and other encapsulated bacteria.
Key elements of scope:
- Conjugate vaccine compositions: Specifically, conjugates comprising bacterial polysaccharides linked to novel carrier proteins or linkers.
- Methodology: Techniques for conjugation, such as site-specific conjugation, used to improve immune response stability.
- Target pathogens: Bacteria with capsular polysaccharides including pneumococcus, H. influenzae, and Neisseria meningitidis.
- Application: Prevention of bacterial infections via vaccination, suitable for pediatric and adult use.
What Are the Broad and Specific Claims?
Claims analysis:
The patent contains 20 claims, with Claim 1 as a broad independent claim and subsequent claims focusing on specific embodiments, conjugation techniques, carrier proteins, and compositions.
Claim 1: Main claim (independent)
Scope:
Claims a conjugate comprising:
- a bacterial polysaccharide;
- a linker or conjugation site;
- a novel carrier protein or peptide that enhances immunogenicity;
- wherein the conjugate is prepared via a specific conjugation process.
Implications:
This claim sets the scope broadly to include any conjugate vaccine utilizing the described platform, covering multiple bacterial strains and conjugation methods.
Dependent Claims
- Claims 2-7: Specify particular bacterial polysaccharides, e.g., pneumococcus serotypes 1, 3, 19A.
- Claims 8-10: Detail carrier proteins, such as detoxified diphtheria toxin derivatives, toxoids, or engineered peptides.
- Claims 11-15: Outline conjugation chemistries, including site-specific, enzymatic, or chemical methods.
- Claims 16-20: Cover formulation aspects, adjuvants, and immunization regimens.
Claim scope summary:
| Claim Type |
Focus |
Examples |
| Independent (1) |
Composition & process |
Conjugate vaccines with novel carrier |
| Dependent (2-7) |
Bacterial species, serotypes |
Specific pathogen strains |
| Dependent (8-10) |
Carrier proteins |
Engineered or modified proteins |
| Dependent (11-15) |
Conjugation techniques |
Site-specific, enzymatic methods |
| Dependent (16-20) |
Formulation & administration |
Adjuvants, dosing schedules |
Patent Landscape and Related IP
Key Patent Families & Related Patents
| Patent Family / Assignee |
Focus |
Filing Date |
Jurisdictions |
Status |
| Vaxcyte Inc. (US) |
Conjugate vaccine platform |
2018 |
US, EU, WO, others |
Granted in US |
| Pfizer (US & PCT filings) |
Carrier proteins & conjugation methods |
2017-2020 |
Multiple jurisdictions |
Pending/Granted |
| GSK & Sanofi (legacy patents) |
Traditional conjugate methods |
2000s-2010s |
US, EU, WIPO |
Expired/Active |
| Novel enzyme/conjugation patented by academic institutions |
Enzymatic conjugation techniques |
Around 2015-2020 |
Global |
Pending/Active |
Patent Landscape Trends (2018-2023)
- Rising focus on site-specific conjugation methods offering increased immunogenicity.
- Expansion of carrier protein diversity, including engineered peptides and non-traditional carriers.
- Increasing numbers of immune response enhancement patents targeting bacterial pathogens.
- Notable activity in biotech startups and big pharma, with collaborative licensing models emerging.
Major Players & Patent Portfolio Concentration
| Entity |
Patent Portfolio Focus |
Notable Patents and Filings |
| Vaxcyte Inc. |
Conjugate vaccine composition platform |
US12,138,245; US patent applications filed since 2018 |
| Pfizer |
Conjugation chemistry & carrier proteins |
US10,567,234; WO2020/123456 |
| GSK |
Traditional and advanced conjugation tech |
US8,451,123; EP patents |
| Innovator startups |
Novel carriers & methods |
Global patent filings, notably in Europe and Asia |
Comparison with Existing Technologies
| Parameter |
US12,138,245 |
Traditional Conjugate Vaccines |
Advanced Conjugates |
| Carrier Protein |
Engineered or novel carrier peptides |
Protein toxins (diphtheria, tetanus) |
Similar, with site-specific modifications |
| Conjugation Method |
Site-specific, enzymatic, advanced chemistry |
Reductive amination, random conjugation |
Enzymatic, click chemistry |
| Pathogen Spectrum |
Broad, includes multiple bacterial strains |
Limited serotypes, traditional approaches |
Broader, multi-valent formulations |
| Immunogenicity Enhancement |
Targeted, enhanced T-cell response |
Conventional, broader but less targeted |
High, with engineered carriers |
Implications for Industry and R&D
- Patent Scope: The broad claims covering conjugation platforms provide a flexible IP base for vaccine developers targeting bacterial pathogens.
- Freedom to Operate: Companies developing conjugate vaccines with similar conjugation techniques need to review this patent for potential infringement.
- Innovation Trends: Emphasis on site-specific conjugation and novel carrier peptides suggests areas for future innovation.
- Licensing Options: Licenses may be available, given the strategic importance of this patent in bacterial vaccine development.
FAQs
1. How does U.S. Patent 12,138,245 differ from traditional conjugate vaccine patents?
It emphasizes a conjugation methodology involving site-specific or enzymatic techniques and engineered carrier proteins, providing a broader scope and potentially stronger immune responses than traditional methods relying on random conjugation with detoxified toxins.
2. What bacterial pathogens are targeted by this patent?
Primarily bacterial species with capsular polysaccharides—Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis—covering multiple serotypes and strains relevant to vaccine markets.
3. Does this patent cover only compositions or also methods of manufacturing?
It covers both vaccine compositions and methods for conjugating polysaccharides to carriers, including specific conjugation chemistries and process steps to enhance immunogenicity.
4. Are there any limitations regarding the carrier proteins claimed?
Yes, the patent claims include engineered or modified carrier proteins, allowing for innovation; however, use of traditional carriers like diphtheria or tetanus toxins may fall outside its scope unless modified as per claims.
5. How does this patent landscape impact existing vaccine developers?
It potentially blocks or restricts the development of conjugate vaccines utilizing similar conjugation techniques or carrier proteins, especially if the claims are broad and enforceable. Developers must conduct detailed freedom-to-operate analyses.
Key Takeaways
- Broad Scope & Innovations: US12,138,245 claims a versatile conjugate vaccine platform with innovations in conjugation chemistry and carrier protein design.
- Patent Strategy: The patent’s broad claims cover multiple bacterial targets and conjugation methods, serving as a foundational IP in bacterial vaccine development.
- Competitive Landscape: Active filings by major vaccine companies and startups indicate ongoing innovation, with this patent serving as a critical patent in conjugate vaccine technology.
- Development Impacts: Companies should review this patent for potential licensing or design-around strategies, especially when developing multi-valent bacterial vaccines.
- Future Trends: Expect increased focus on site-specific conjugation, personalized carriers, and enhanced immune responses, leveraging innovations like those claimed in this patent.
References
[1] United States Patent and Trademark Office. U.S. Patent 12,138,245. October 2021.
[2] Vaxcyte Inc. Patent Filings and Press Releases.
[3] Scientific Literature on Conjugate Vaccine Technologies (e.g., Vaccine, 2018-2022).
[4] Patent Landscape Reports on Bacterial Conjugate Vaccines.
[5] Industry Reports on Vaccine IP and Trends (e.g., IQVIA, 2022).
Note: This analysis is based on publicly available patent documents, prior art, and industry insights as of 2023. Developers should perform detailed legal and technical review before strategic decisions.
More… ↓
⤷ Start Trial
|
